Forbion Capital Partners

ALGEMENE INFORMATIE

Bezoekadres
Gooimeer 2-35
1411 DC Naarden

Postadres
Postbus 5187
1410 AD Naarden

Tel: 035 699 30 00
Fax: 035 699 30 01
Contactpersoon
V. van Houten
Directie
S.J.H. van Deventer, G.J. Mulder, M.A. van Osch, H.A. Slootweg
  • BEKIJK DE WEBSITE
Forbion Capital Partners (Forbion) is a leading venture capital firm that works closely with entrepreneurs to build life sciences companies with technologies and products designed to transform people’s lives. Forbion currently manages six closed-end funds with commitments exceeding EUR 700m, including its $200m+ FCFIII fund, launched in 2016. Forbion is actively looking for new, exciting opportunities in Europe and North America. To this end Forbion has a team of ten investment professionals across two offices, in Naarden (NL) and Munich (DE) plus representation in Boston (USA). Forbion’s underlying portfolio theme is investing in private companies developing novel drugs, medical devices and diagnostics for high, or even unmet, medical needs. Forbion helps such companies to bridge research and development, not just financially via its six funds, but also through its team members’ expertise. Its current portfolio comprises around 27 active investments in companies working on a range of globally important disease areas of high (unmet) medical need. Portfolio companies are typically working in the fields of cancer, kidney disease, liver disease, dyslipidemia, inflammatory bowel disease, anti-infectives, central nervous system, pain management and the microbiome. Recent examples of successful investments include Dezima Pharma sold to Amgen for up to $1.55bn and the sale of Acerta Pharma to Astra Zeneca for a total exit value of $7bn (investment by Forbion’s affiliate BioGeneration Ventures). Forbion also operates a joint venture with BioGeneration Ventures, who manage three separate seed and early stage funds focused on Benelux.

BioGeneration Ventures manage funds that are actively investing venture capital in the next generation of successful Biotech companies in Europe with a focus on The Netherlands, Belgium and Germany. BioGeneration focuses on high- potential companies active in therapeutics, medical devices, and diagnostics areas. The team of BioGeneration Ventures has a successful track record and broad experience in the life sciences sector. Its involvement goes beyond a mere financial investment. Having worked in both the startup environment as well as established industry players BioGeneration’s strategy is to generate value by working very closely with its portfolio companies and provide active hands-on support. BioGeneration has achieved numerous successful exits and has shown a very strong fund performance. On 1 July 2016, BioGeneration had a first closing of its third Fund BGV III from which it is currently investing.
Forbion Capital Partners (Forbion) is a leading venture capital firm that works closely with entrepreneurs to build life sciences companies with technologies and products designed to transform people’s lives. Forbion currently manages six closed-end funds with commitments exceeding EUR 700m, including its $200m+ FCFIII fund, launched in 2016. Forbion is actively looking for new, exciting opportunities in Europe and North America. To this end Forbion has a team of ten investment professionals across two offices, in Naarden (NL) and Munich (DE) plus representation in Boston (USA). Forbion’s underlying portfolio theme is investing in private companies developing novel drugs, medical devices and diagnostics for high, or even unmet, medical needs. Forbion helps such companies to bridge research and development, not just financially via its six funds, but also through its team members’ expertise. Its current portfolio comprises around 27 active investments in companies working on a range of globally important disease areas of high (unmet) medical need. Portfolio companies are typically working in the fields of cancer, kidney disease, liver disease, dyslipidemia, inflammatory bowel disease, anti-infectives, central nervous system, pain management and the microbiome. Recent examples of successful investments include Dezima Pharma sold to Amgen for up to $1.55bn and the sale of Acerta Pharma to Astra Zeneca for a total exit value of $7bn (investment by Forbion’s affiliate BioGeneration Ventures). Forbion also operates a joint venture with BioGeneration Ventures, who manage three separate seed and early stage funds focused on Benelux.

BioGeneration Ventures manage funds that are actively investing venture capital in the next generation of successful Biotech companies in Europe with a focus on The Netherlands, Belgium and Germany. BioGeneration focuses on high- potential companies active in therapeutics, medical devices, and diagnostics areas. The team of BioGeneration Ventures has a successful track record and broad experience in the life sciences sector. Its involvement goes beyond a mere financial investment. Having worked in both the startup environment as well as established industry players BioGeneration’s strategy is to generate value by working very closely with its portfolio companies and provide active hands-on support. BioGeneration has achieved numerous successful exits and has shown a very strong fund performance. On 1 July 2016, BioGeneration had a first closing of its third Fund BGV III from which it is currently investing.  

PROFIEL

  • Sectoren/branches
  • Life Sciences
  • Financieringsfasen
  • Expansie / groei
  • Seed
  • Start
  • Investering
  • 250.000 - 2 mln
  • 2 mln - 5 mln
  • 5 mln - 20 mln
  • Regio's
  • Benelux
  • Duitsland
  • Europa
  • Nederland
  • Belegger in fonds
  • Institutioneel
#
#

NVP (Geassocieerde) leden

  • Strong Root Capital
  • Accuracy Netherlands B.V.
  • Wadinko N.V.
  • Spring Associates B.V.
  • BDO Corporate Finance B.V.
  • Committed Capital Management
  • Alvarez & Marsal
  • CORP.
  • Prime Ventures
  • InvestInFuture